We recently published a list of the Jim Cramer Just Discussed These 13 Stocks. In this article, we are going to take a look ...

Bristol-Myers Squibb faces patent risks but has promising new drugs. Find out why BMY stock remains a "Buy" with strong ...

Shares of Bristol-Myers Squibb Co. rose by about 1% on Monday afternoon following an upgrade from Jefferies. The brokerage ...

Adakitug is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Solid Tumor.

Investing.com -- Jefferies upgraded Bristol-Myers Squibb Company (NYSE ... highlighted the potential of BMY’s schizophrenia drug, Cobenfy, forecasting it to become a $10 billion-plus product.

Bristol-Myers Squibb Inc. (NYSE: BMY) shares saw are trading higher Monday. Jefferies analyst, Akash Tewari, raised his ...

Lilly's and Bristol Myers Squibb's plans, prompting lawsuits. Sanofi simply proceeded without an OK. The hospital industry warns if the drug companies prevail, that would hamper HRSA's authority ...

Ionis Pharmaceuticals is advancing the investigational RNA-targeted therapy olezarsen for the treatment of familial ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE ... middleman that makes more money frankly than the drug companies. And they don't do anything except ...